Quest Diagnostics Incorporated (DGX)
Quest Diagnostics Incorporated operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Secaucus, NJ, US. The stock last traded at $246.67, up 3.69% on the session, giving a market capitalisation of $27.23B. On trailing twelve-month figures it carries a trailing P/E of 25.86, a net margin of 9.2%. Its beta of 0.55 implies it has historically moved less than the broad market.
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
Quest Diagnostics Incorporated is most often compared with the following Healthcare names: